Home > Cardiology > HFA 2022 > GALACTIC-HF: Omecamtiv mecarbil option for HFrEF patients with low SBP

GALACTIC-HF: Omecamtiv mecarbil option for HFrEF patients with low SBP

Presented By
Prof. Marco Metra, University of Brescia, Italy
Conference
HFA 2022
Trial
GALACTIC-HF
Although patients with heart failure and reduced ejection fraction (HFrEF) and low systolic blood pressure (SBP) displayed a higher risk of HF outcomes in a subanalysis of the GALACTIC-HF trial, treatment with omecamtiv mecarbil reduced this risk more distinctively than in those with a higher SBP. Since placebo and omecamtiv mecarbil showed similar safety profiles, this agent may be a valid option for the hard-to-treat population of patients with HFrEF and low SBP. “Patients with HFrEF and low SBP are at increased risk of clinical events and do not tolerate guideline-directed medical therapy well,” explained Prof. Marco Metra (University of Brescia, Italy) [1]. “Omecamtiv mecarbil is a selective cardiac myosin activator that improves cardiac function, without reducing blood pressure.” Therefore, this agent may be useful in these patients. Prof. Metra and colleagues analysed the efficacy and safety of omecamtiv mecarbil in patients with HFrEF and lo...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on